Treating Type 1 Diabetes
A piece about Sanofi partnering with a monoclonal antibody developer to treat type 1 diabetes generated a lot of clicks. It was the top story last month.
Teplizumab has the potential to become a first-in-class and first disease-modifying therapy for type 1 diabetes. The drug candidate is an anti-CD3 monoclonal antibody that counteracts immune cells that destroy insulin-producing beta cells in type 1 diabetes.
Photo credit: GettyImages/Maskot
